StayWell to Offer Exclusive Webinar on High-tech, High-touch Patient Engagement for Health Plan Leaders

Share Article

June 8 webinar features new StayWell patient engagement software platform that enhances communication among clinicians, patients and payers.

Nicole Latimer, CEO, StayWell

Value-based care is driving the way health care is being delivered and experienced by patients, which makes it critically important that engagement is imbued in all phases of the patient journey.

Chronic conditions account for 86 percent of U.S. health care spending. Third-party payers, including health plans, are increasingly exploring the use of digital technology solutions to complement patient engagement strategies that involve patients in the care they receive. The goal of implementing these digital solutions is to help improve clinical outcomes and lower overall health care costs.

The StayWell Company, a leading health solutions provider, announced today that CEO Nicole Latimer will lead a webinar for health plan leaders on high-touch, high-tech, digital solutions that help manage risk and avoid clinical complications while producing better financial outcomes and healthier patients. Health care professionals can register for the webinar on June 8 at 2 p.m., EST by visiting

“Value-based care is driving the way health care is being delivered and experienced by patients, which makes it critically important that engagement is imbued in all phases of the patient journey,” said Latimer. “A digital solution that enhances and extends clinician-member-payer communication beyond the care setting can help close gaps in care, foster patient compliance, support treatment decisions, promote higher quality care, and lower costs.”

During the webinar, participants will also learn more about StayWell’s digital solution, Krames CareEngage™, an interactive patient engagement platform that features modules with customizable patient checklists, patient engagement tools, and patient educational materials for treating chronic conditions, such as diabetes. A clinician can deliver an easy-to-use module directly to a patient’s desktop, tablet or smartphone.

The Krames CareEngage platform currently features CareEngage Prepare™, which targets pre- and post-surgical outcomes, and CareEngage Sustain™, which targets chronic condition management.

The platform, powered by Doctella Smartlist™ technology, originated from quality and safety checklist research performed by Peter Pronovost, MD, PHD, of Johns Hopkins University School of Medicine. It can be integrated into current workflows and Electronic Health Record (EHR) systems.

Latimer will demonstrate CareEngage Sustain, which specifically targets diabetes management, during the June 8 webinar.

The CareEngage platform combines StayWell’s 40 years of expertise in clinical content and patient engagement with Silicon Valley-developed digital technology to address concerns related to costs, patient compliance, behavior change, safety and clinical outcomes for treating chronic conditions.

About StayWell
StayWell is a health solutions company that uses the science of behavior change to help people live happier, healthier lives. StayWell brings decades of experience working across the health care industry to design solutions for improving individual and organizational health outcomes, managing the health of targeted populations, and creating brand engagement for employers and health care organizations. StayWell programs have received numerous top industry honors, including the C. Everett Koop National Health Award and the Web Health Award for health engagement programs. StayWell also has received URAC and NCQA accreditation for several of its programs. StayWell is majority-owned by Healthcare Services & Solutions, LLC, a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (“Merck”). The company is headquartered in Yardley, PA, and also has a major location in St. Paul, MN. To learn more, visit or connect with on Twitter, Facebook, and LinkedIn.

About Merck
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of The StayWell Company, a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

Media contact for StayWell:
Barbara Tabor, APR / 651-230-9192 / barbara(at)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Barbara Tabor
tabor PR
+1 651-230-9192
Email >